Phytotransit

General characteristics. Structure:

Active ingredient: 0,49 g of a laminaria of a thallus.

Excipients: silicon dioxide colloid stearate of calcium.

Pharmacological properties:

Pharmacodynamics. Has laxative, thyroid and hypolipidemic effect. Laxative action is caused by ability of drug to bulk up and, increasing in volume, to cause irritation of receptors of a mucous membrane of intestines.

Indications to use:

Chronic atonic lock, including at patients with a lipidemia.

Route of administration and doses:

Apply inside till 6-12 tablets once a day. Tablets are swallowed or chewed, washing down with enough water. Course of treatment of 15-30 days.

Features of use:

Use at pregnancy and during breastfeeding. Drug should not be used at pregnancy and during breastfeeding.

Side effects:

At prolonged use and hypersensitivity to iodine the iodism phenomena (cold, urticaria, a Quincke's edema, hypersalivation, dacryagogue, acne rash, etc.), allergic reactions (a skin itch, a dermahemia) are possible.

Interaction with other medicines:

Interaction of drug of Fitotranzit with other medicines is not described.

Contraindications:

The increased individual sensitivity (including to iodine), a hyperthyroidism, a multinodal craw, a thyrotoxicosis of various genesis, nephrite, a nephrosis, hemorrhagic diathesis, a furunculosis, acne rash, a chronic pyoderma, intestinal impassability, a syndrome of a "acute" stomach, inflammatory diseases of an abdominal cavity (including appendicitis), acute feverish states, children's age up to 18 years.

Overdose:

So far overdose cases at use of drug of Fito-Transit are not registered.

Storage conditions:

Period of validity - 3 years.

Issue conditions:

Without recipe

Packaging:

On 20 tablets in blister strip packagings, on 1, 2, 3 or 4 strip packagings in a cardboard pack. On 40, 60 or 80 tablets in polymeric banks, after 1 bank in a cardboard pack.